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INTRODUCTION
Diabetic neurological complications continue to progress in
asubstantialfractionofpatientsdespitebesteffortsatglycemic
control.Thedevelopmentofadjuvanttreatmentstosupplement
diet,exercise,oralhypoglycemicagents,andinsulinisurgently
needed and may do much to enhance the quality of patient life.
Theneurobiologyofinsulin-likegrowthfactors(IGFs)hasbeen
studied in animals, and a loss of IGF activity produces neuro-
logical disorders that mimic the disturbances of diabetic neu-
ropathy. The theory that a decline in IGF neurotrophic activity
is pathogenic for diabetic neuropathy has efﬁciently generated
many testable hypotheses. The theory predicts and tests show
that IGF levels are reduced in diabetic primates, including hu-
mans, and that IGF gene expression is reduced throughout the
peripheralandcentralnervoussystemindiabeticrodents.Tests
further show that replacement doses of IGFs can prevent an
array of diabetic neurological disturbances in the peripheral
and central nervous system. These data point to a common eti-
ology for central and peripheral neurological disturbances. It
is of considerable practical and theoretical interest that IGF
treatment is effective independently of ongoing hyperglycemia
and metabolic imbalance. These observations are in line with
emerging clinical data showing that new drugs can be devel-
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oped speciﬁcally for the treatment of diabetic complications,
albeit not targeted at glycemic control. The pharmacokinetic
and safety proﬁles support the movement of IGFs toward clin-
ical trials.
CLINICAL DIABETIC NEUROPATHY
There are two types of diabetic patients. Type II diabetes
is previously known as non–insulin-dependent diabetes melli-
tus (NIDDM) or adult-onset diabetes. Generally striking late in
adulthood, these patients produce normal or elevated amounts
of insulin, but are resistant to insulin. Type II diabetes has a 5%
to 7% incidence in the general population, and comprises more
than 90% of all diabetic patients, or about 14 million people
in the United States alone. The incidence is rising as a conse-
quence of the increasing population age, industrialization, and
obesity.Furthermore,HispanicsandAfrican-Americanshavea
higher overall incidence than Caucasians, and their proportion
in the general population is increasing. The remaining 10%
have type I diabetes, previously known as insulin-dependent
diabetes mellitus (IDDM) or juvenile-onset diabetes. They are
unabletoproducesufﬁcientamountsofinsulinduetopancreatic
insufﬁciency, in most cases believed to arise as an autoimmune
disorder.
Type I and type II diabetic patients are at risk for diabetic
neuropathy. The major pathological feature is a dying-back
axonopathy that involves both unmyelinated and myelinated
axons. There is a dwindling of axon calibers, reduced axonal
transport, loss of synapses, loss of axons, and, ultimately, loss
ofneurons.Dailywear-and-tearonthenervoussystemrequires
ability for nerve regeneration, and the poor nerve regenera-
tion associated with diabetes may explain the loss of synapses,
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dying-back axonopathy, and loss of neurons. There is reduced
conductionvelocityinabout90%ofpatients,butitsrelationship
to clinically meaningful neuropathy remains uncertain because
a signiﬁcantly smaller fraction of patients progress to diabetic
neuropathy, and axons can regenerate even when conduction is
blocked by tetrodotoxin. The sensory, sympathetic, and motor
systems may be variably afﬂicted.
Muscular atrophy and weakness can develop secondary to
motor involvement. Autonomic neuropathy includes gastro-
paresis with abdominal bloating and pain, loss of bladder tone
thatsometimesrequirescatheterization,abnormalcardiovascu-
lar function, silent myocardial infarct, and sudden death. Half
of affected males have impotence. The most prevalent form of
this complication is a symmetrical sensory neuropathy. Burn-
ing unremitting pain, such that a patient cannot bear even the
weightofabedsheet,issometimesencountered.Withprogres-
sion, there is loss of sensory function, leading to the inability
to do simple tasks, such as turn the pages of a book. Inability to
perceive pain and touch as well as impaired proprioceptors re-
sults in an increased tendency for injuries. In conjunction with
poor wound healing and increased susceptibility to gangrene,
approximately 100,000 limb amputations are performed on di-
abetic patients each year (Bild et al., 1989; Litzelman et al.,
1993). For other manifestations of clinical neuropathy, reviews
and monographs on diabetic neuropathy are available (Thomas
and Tomlinson, 1993; Vinik et al., 1996; American Diabetes
Association, 1993).
INTENSIVE GLUCOSE THERAPY DOES NOT
PREVENT THE PROGRESSION OF DIABETIC
COMPLICATIONS IN A LARGE FRACTION
OF PATIENTS
The Diabetes Control and Complications Trial (DCCT) has
shown that intensive insulin therapy reduces the incidence of
neuropathy in 60% of highly selected type I diabetic patients
(DCCT Research Group, 1993). This is a very important clini-
cal ﬁnding. Unfortunately, neuropathy continues to progress in
40% of patients, despite the best current method for diabetic
treatment, showing that there is a need for new treatments in
addition to glycemic control. A treatment that could amelio-
rate, prevent, and/or reverse diabetic neuropathy would be a
major therapeutic advance, and would help reduce the nearly
$100 billion overall cost of health care for diabetic patients. A
disproportionately high fraction of this amount is expended for
those patients with complications such as neuropathy.
The development of supplemental treatments for diabetic
complications is particularly desirable, because intensive in-
sulintherapyisnotbenign,andisassociatedwithathreefoldin-
creasedriskoflife-threateninghypoglycemia.Extremecaution
iswarrantedbecause43%ofseverehypoglycemicepisodesare
found to occur during sleep. Diabetic patients with neuropathy
may be particularly susceptible to severe hypoglycemia un-
der intensive insulin therapy (Hoeldtke et al., 1982; Santiago
etal.,1984).Thesepatientsmayhaveimpairedautonomicfunc-
tionand,thereby,adiminishedcounterregulatorysystemtoop-
pose hypoglycemia. Mortality can be increased (Teutsch et al.,
1984).
Oral monotherapies have been unable to achieve the goal
of intensive therapy in type II diabetic patients, but a combi-
nation of insulin, oral agents, and diet can partially reduce di-
abetic complications (UK Prospective Diabetes Study Group,
1998). Intensive therapy reduced hemoglobin (Hb)A1C levels
byapproximately1%belowresultsachievedwithconventional
therapy, resulting in a 35% reduction in the risk of complica-
tions. Therefore, complications continue to progress in a large
fraction of patients in spite of the best current methods of glu-
cose control. The incidence of major hypoglycemic adverse
events is 2.3% of patients per year. Thus, it is very important
forbothtypeIandtypeIIdiabeticpatientstomanagebloodglu-
coseasclosetonormalaspossible,andtherapiestosupplement
glycemiccontroltospeciﬁcallytreatdiabeticcomplicationsare
much needed.
SUPPLEMENTAL THERAPIES THAT DO NOT
TARGET GLYCEMIC CONTROL ARE
CLINICALLY EFFECTIVE IN PREVENTING
DIABETIC COMPLICATIONS
High blood pressure and microalbuminuria are risk factors
for the progression of nephropathy in diabetic patients. Like
other diabetic complications, it has long been believed that
nephropathy is due mainly to hyperglycemia. However, recent
data challenge this belief. There is a 50% reduction in end-
stagerenaldiseaseandmortalityinpatientswithtypeIdiabetes
treated with angiotensin-converting enzyme inhibitors (Lewis
etal.,1993).Moreover,thereisa70%reductionintheprogres-
sion to nephropathy in type II diabetic patients with microal-
buminuria when treated with angiotensin-II receptor blockers
(Parving et al., 2001). Control of hypertension is important
as well. The IGF data are consistent with these observations
that diabetic complications can be prevented independently of
glycemic state.
OVERVIEW OF THE IGF SYSTEM
The IGF genes are quite large and each is unique in verte-
brates. Alternative exon usage, splicing, and multiple poly(A)
terminationsitesproducemultipleIGF-IandIGF-IItranscripts.
Because all IGF transcripts encode the complete prepro-IGF
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complex, tissue-selective regulation of gene expression. The
IGF-I gene is under growth-hormone control in certain tissues
such as liver, but is also responsive to developmental signals,
nutritional status, diabetes, aging, and neural activity. The IGF-
II gene is likewise responsive to developmental signals, nutri-
tional status, diabetes, aging, and neural activity. However, it is
not responsive to growth hormone. In the adult rat, the highest
levelsofIGF-IIgeneexpressionarefoundinbrain,spinalcord,
andperipheralnerves.Itisexpressedinliverinhumans,butnot
rats, due to absence of the hepatic promoter. Hence, circulating
IGF-II is abundant in humans but essentially absent in adult
rodents. The IGF-I gene is likewise expressed in adult brain,
spinal cord, peripheral nerves, and liver, but its expression is
more widespread among other tissues as well. IGF-II is by far
the predominant IGF in brain.
IGF-I and IGF-II are protein hormones (molecular weight
7.5 kDa) comprised of a single polypeptide chain held together
bythreeintrachaindisulﬁdebonds.IGFsaremembersofthein-
sulin gene family; they are endocrine, autocrine, and paracrine
factors. Both IGF-I and IGF-II bind to the type I IGF recep-
tor, and it is believed that most actions of IGFs are through
this receptor. The type I receptor is a plasma membrane–bound
heterodimer homologous to the insulin receptor where the ex-
tracellular α subunits contain the IGF-binding domain, and an
intracellular domain of the β subunit is a tyrosine kinase. The
type I receptor is present on all or virtually all neurons, and
is localized to the cell body, axons, and nerve terminals. This
receptoronbrainneuronsissmallerthanthoseonperipheraltis-
sues due to decreased glycosylation of the α subunits, and does
not appear to gate glucose uptake. In addition, IGF-II binds the
typeIIreceptorthatiscomprisedofasinglepolypeptidelocated
in the plasma membrane and devoid of tyrosine kinase activity.
It appears to be involved in IGF-II degradation and lysosomal
targeting, and may also signal possibly through a G-protein
mechanism. Because their three-dimensional structures resem-
ble that of insulin, IGFs can cross-occupy insulin receptors, but
this occurs only at supraphysiological concentrations.
There are six members of an IGF-binding protein (IGFBP-1
through -6) family that sequester IGFs. Circulating IGFs form
a trimeric complex, predominantly with IGFBP-3, and the acid
labilesubunit.IGFsintheextracellularﬂuid,ontheotherhand,
are generally in the form of dimers together with one of the
IGFBPs. It is believed that tissue proteases may act on these
dimers to regulate the availability of free IGFs.
It is instructive to consider the major additive sources of
IGFs for the nervous system. Neurons have access to IGFs
produced in brain, spinal cord, and peripheral nerve. In ad-
dition to these autocrine/paracrine sources of IGFs, circulating
endocrine sources of IGFs, primarily from liver, can provide
further support for peripheral neurons. Because the signaling
type I IGF receptor binds to both IGF-I and IGF-II, these
two neurotrophic ligands form a redundant back-up system
for one another. The onset of neuropathy may be slower in
humans because hepatic IGF-II production provides back-up
neurotrophic support to partially offset the loss of circulating
IGF-I in younger diabetic patients, whereas the onset may be
more rapid in adult diabetic rats due to the absence of circulat-
ing IGF-II. It will be seen that in diabetes there is a progressive
lossofautocrine,paracrine,endocrine,andredundantIGFneu-
rotrophic support. Such loss is proposed to increase the risk of
neuropathy.
NEUROBIOLOGY OF IGFs
A brief review of the neurobiology of IGFs helps to explain
how IGFs are implicated in diabetic neuropathy. The strength
of this model is that diabetic neurological disturbances can be
rationally understood from the biochemistry and physiology of
IGF action in the nervous system.
IGFs are neurotrophic factors that can support and prevent
damage to neurons. The neurotrophic properties of IGF-I and
IGF-II were initially discovered in the 1980s. IGF-I and -II
were found to induce neurite outgrowth and support survival
in cultured sensory, sympathetic, and human neuroblastoma
cells (Recio-Pinto and Ishii, 1984; Ishii et al., 1985; Recio-
Pinto et al., 1986). These studies were soon extended to show
that IGFs can support a wide variety of central nervous system
(CNS) as well as peripheral nervous system (PNS) neurons.
The cloning and sequencing of the rat IGF-I (Shimatsu and
Rotwein, 1987) and IGF-II (Soares et al., 1985, 1986) genes
permittedexaminationoftheirtissue-speciﬁcanddevelopmen-
tal expression. The IGF-II gene is selectively expressed at the
highest levels in the brain, spinal cord, and peripheral nerves
among tissues of the adult rat. The IGF receptors are found on
neuronsaswellasglialcells.TheexpressionoftheIGF-IIgene
is closely correlated with the development of synapses (Ishii,
1989). IGFs can increase neurite (axon and dendrite) growth
in cultured neurons (Recio-Pinto and Ishii, 1984; Recio-Pinto
et al., 1986), by increasing the expression of the genes that
encode structural proteins of axons, such as tubulins and neu-
roﬁlaments (Mill et al., 1985; Wang et al., 1992). Highly pu-
riﬁed recombinant human IGF-I and IGF-II can increase axon
growth and support survival of neurons cultured from various
parts of the central (brain and spinal cord) and peripheral ner-
vous systems. Overexpression of IGF-I in brain of transgenic
mice results in brains 55% larger than normal (Mathews et al.,
1988), and mouse strains with reduced IGF-I levels have un-
derdeveloped brains (Noguchi et al., 1986; Beck et al., 1995).
IGFsappeartobeabletoactonallorvirtuallyallneuronsinthe
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Various data suggest that the normal role of IGFs is to
help maintain the nervous system in adult mammals, includ-
ing humans. IGF treatment can help repair damaged nervous
systems. Administration of recombinant human IGF-I (Kanje
et al., 1989) or IGF-II (Glazner et al., 1993) was found to sig-
niﬁcantly increase the rate of sensory nerve regeneration in
adult rats. IGF-II administration increases motor nerve regen-
eration as well (Near et al., 1992). IGFs are normally produced
in nerves, and IGF genes are turned on to help damaged nerves
regenerate (Glazner et al., 1994). Following sciatic nerve tran-
section in neonatal rats, IGF-II administration can prevent loss
of motoneurons (Pu et al., 1999a). These results demonstrate
that IGF treatment can help repair damaged peripheral nerves
in a mammal.
Although the central effects of IGFs are not discussed here,
what has emerged is the concept that IGFs are circulating and
CSF neurotrophic factors that provide general support to virtu-
ally all neurons within the PNS and CNS. Other neurotrophic
factors, such as neurotrophins (nerve growth factor [NGF],
brain-derived nerve factor [BDNF], neurotropin-3 [NT-3]) pro-
vide additional support for select populations of neurons. Re-
view articles may be consulted on the neurobiological actions
of IGFs (Recio-Pinto and Ishii, 1988; de Pablo and de la Rosa,
1995; D’Ercole et al., 1996; Ishii and Pu, 1999). These data
showthebroadpotentialthatIGFshavetotreatthemanydiffer-
ent types of cells of the central and peripheral nervous systems.
LOSS OF IGF CAUSES NEUROLOGICAL
DISTURBANCES THAT MIMIC THOSE
OBSERVED IN DIABETES
BlockingofIGFactivityinnormal,nondiabeticanimalswill
produceneuropathywithcharacteristicssimilartothatobserved
indiabetes.Forexample,anti-IGFantibodiescanblocksensory
andmotornerveregenerationinnormalrats(Kanjeetal.,1989;
Near et al., 1992; Glazner et al., 1993), and nerve regeneration
is impaired in diabetes. Neuron loss may occur in clinical di-
abetes in both the peripheral and central nervous systems, and
this is observed in rats treated with an anti-IGF antiserum (Pu
et al., 1999a) and in IGF-I–null mice (Beck et al., 1995). Con-
duction velocity (rate at which electrical signals travel down
nerves) and axonal diameters are reduced in diabetic patients,
andalsoinIGF-I–knockoutmice(Rabinovskyetal.,1996;Gao
et al., 1999). IGF-I administration can reverse the low motor
and sensory nerve conduction velocity in these mice. These
datashowthelossofIGFactivityisariskfactorforneuropathy
independently of hyperglycemia.
IGFs can increase α-tubulin, β-tubulin, 68-kDa neuroﬁla-
ment, and 170-kDa neuroﬁlament gene expression (Mill et al.,
1985; Wang et al., 1992). Consequently, a decline in IGF gene
expressionindiabetesisconjecturedtocausediabeticbiochem-
ical disturbances, including reduced neuroﬁlament and tubulin
production in nerves, and tubulins are needed for assembly of
microtubules. Neuroﬁlaments regulate axonal diameters, and
axonal diameters are reduced in diabetes. The absence of ade-
quate amounts of these major cytoskeletal proteins may result
in loss of synapses and axons. Tubulins further provide tracks
on which axonal transport depends, and axonal transport is dis-
rupted in diabetes. The metabolic need would be greatest for
the longest axons, and this may underlie the length-dependent
axonopathy in diabetes.
THEORY FOR IGF INVOLVEMENT IN THE
PATHOGENESIS OF DIABETIC NEUROPATHY
IGFs support the types of neurons afﬂicted in diabetes,
namely sensory, sympathetic, and motor. The theory is pro-
posed that both insulin and IGFs are required to maintain the
properfunctioningofthenervoussystem,andthatthereisade-
cline in insulin and IGF activity in diabetes that predisposes to
neuropathy(Ishii,1995).Inbrief,insulin,IGF-I,andIGF-IIare
proposed to provide redundant neurotrophic support for neu-
rons. This theory predicts that (i) IGF activity is reduced in
diabetes; (ii) neuropathy can be prevented by administration of
IGFs;(iii)centralandperipheralneurologicaldisturbancesmay
shareacommonetiologyinvolvingIGFs;(iv)neuropathymight
betreatableirrespectiveofhyperglycemia;(v)differencesinthe
manner in which rats and humans develop neuropathy can be
explained at least in part by a species-speciﬁc difference in the
pattern of IGF gene expression; and (vi) an age-dependent loss
ofIGFmayexplaintheage-dependentriskofneuropathy.Mul-
tifactorial risk is inherent in this formulation, and the total IGF
activity in an individual would depend, for example, on regu-
lation of IGF gene expression, IGF transcript processing, IGF
protein synthesis and turnover rates, IGF BP levels, proteases
that may govern availability of IGF sequestered to binding pro-
teins, IGF receptors, postreceptor signaling, and other factors.
Predictions and tests of the theory are discussed below.
IGF Levels are Reduced in Animal
and Human Diabetes
Humans and Rhesus Monkeys
IGF levels are reduced in diabetic patients. Early clinical
studiesdidnotcontrolforage,andfailedtoﬁndadeclineinIGF
activity in diabetes. However, later studies, using age-matched
patient groups, found that IGF-I level is signiﬁcantly reduced
by 40% to 50% in type I as well as type II diabetes (Tan and
Baxter, 1986; Arner et al., 1989; Ekman et al., 2000). IGFBP-1
circulating levels are elevated, and this is expected to sequester
and reduce the activity of IGFs (Crosby et al., 1992). Diabetic
patients with neuropathy have lower serum IGF-I levels versusIGF REPLACEMENT THERAPY 261
diabetic patients without neuropathy or nondiabetic patients
(Migdalis et al., 1995; Guo et al., 1999). Reduced numbers of
IGF-Ireceptorsarefoundonredbloodcellsofdiabeticpatients
(Haruta et al., 1989; Migdalis et al., 1995). Serum IGF-I levels
are not correlated with glycemic control, measured as HbA1C
levels, in type I diabetic patients treated with insulin (Ekman
et al., 2000). This observation may explain why neuropathy is
not better controlled in insulin-treated patients.
It is critical to recognize that there is an age-dependent de-
cline of IGFs in humans in the later decades of life (Hall and
Sara, 1984). This may explain the age-dependence of clinical
neuropathy (Pirart, 1978), and the increased incidence of neu-
ropathy after the fourth decade of life. Thus, neurons suffer the
loss of IGF neurotrophic activity as a consequence of diabetes,
and IGF levels decline further with advancing age slowly over
decades.
NeuropathymaybelessprevalentintypeIjuvenilediabetics
who are adolescents or young adults, because IGF-I and IGF-II
activities remain relatively high in these age groups. However,
in ketotic episodes IGF-I levels transiently decline, and there is
transient neuropathy (Rieu and Binoux, 1985).
Young rhesus monkeys are lean and have normal glucose
tolerance. As animals age, they become obese and develop im-
paired glucose tolerance, but have normal or slightly elevated
insulin levels. Later, they become overtly type II diabetic. It
is fascinating that there is a decline in IGF-I activity with ev-
ery stage in the progression towards diabetes (Bodkin et al.,
1991). IGF-I levels are observed to decline in the prediabetic
state prior to overt hyperglycemia. Thus, IGF-I levels are not
correlated with glucose levels in neither monkeys nor humans.
Neuropathy is known to develop (Cornblath et al., 1989). The
rhesus monkey provides important support for the theory in
animals genetically close to humans, and shows further the re-
lationship between age-dependent decline in IGF activity and
age-dependent risk of diabetic neuropathy.
Type I Diabetic Rats
IGF-Igeneexpressionisprofoundlyreducedinliver,adrenal
glands,andspinalcordsofstreptozotocin(STZ)-diabeticrats,a
modeloftypeIdiabetes(Ishiietal.,1994).IGF-IIgeneexpres-
sion is reduced in diabetic rat brain (Wuarin et al., 1996). The
signiﬁcant decrease in poly(A)+RNA content per milligram
brain tissue (Wuarin et al., 1996) may be related to the progres-
sive cerebral atrophy in the brains of diabetic patients (Araki
etal.,1994).IGF-IandIGF-IImRNAcontentisreducedinsci-
atic nerves early after the induction of diabetes (Wuarin et al.,
1994), most likely in Schwann cells (Pu et al., 1995). IGF-I
mRNAanditsreceptormRNAlevelsarereducedinspinalcord,
superior cervical ganglia (Bitar et al., 1997; Bitar and Pilcher,
1998),anddorsalrootganglia(Craneretal.,2002).Ratsquickly
develop neuropathy because of a profound loss of neurotrophic
activity involving insulin, IGF-I, and IGF-II. IGF-II activity is
developmentally down-regulated (Soares et al., 1985; 1986),
insulin activity is reduced experimentally, and IGF-I activity
falls secondary to diabetes.
Type II Diabetic Rats
The ZDF (fa/fa) rats provide a genetic model of type II di-
abetes. These rats are obese and become spontaneously hyper-
insulinemic and diabetic at about 5 to 6 weeks of age. IGF-II
gene expression is reduced in brain, spinal cord, and peripheral
nerves in adult diabetic (fa/fa) versus nondiabetic (+/+) litter-
mates (Zhuang et al., 1997; Wuarin et al., 1996). The brains
of (fa/fa) rats are smaller. IGF-I gene expression is reduced in
liver, but not in spinal cord or nerves. IGF-I, rather than IGF-II,
is responsible for regulating the rate of axon elongation during
nerve regeneration (Pu et al., 1999). Because nerve IGF-I gene
expression is not reduced, nerve regeneration does not appear
to be impaired in type II diabetic rats. This is in contrast to
the type I diabetic rat where nerve IGF-I gene expression is re-
duced and regeneration is impaired. These ﬁndings in rats is in
accordance with clinical data showing that nerve injury is more
extensive in type I than type II disease.
These data show that the IGF genes are under complex reg-
ulation, and largely independent of hyperglycemia. IGF lev-
els are reduced in the prediabetic state prior to hyperglycemia,
and reduced further as a consequence of aging. It is instruc-
tive that IGF-I and IGF-II gene expression are increased in
cultured hepatocytes directly in response to insulin (Phillips
et al., 1991; Goya et al., 2001). Consequently, IGF gene ex-
pression may decline in diabetes partially as a consequence
of the reduction in insulin activity rather than in response to
hyperglycemia. Because IGF-I treatment can normalize brain
IGF-II gene expression in diabetic rats independently of hyper-
glycemia (Armstrong et al., 2000), there may be a cascade in
which a reduction of insulin activity leads to a decline in IGF-I
and a secondary decline in IGF-II. Because of complex regula-
tion, insulin may be able only to partially restore IGF levels in
diabetic patients.
Replacement IGF Doses Prevent or Reverse
Neuropathy in Diabetic Rats
Biochemical and electrophysiological measurements, al-
though interesting, are often difﬁcult to relate directly to symp-
tomaticclinicaldisturbances.Forexample,conductionvelocity
isreducedinvirtuallyalldiabeticpatients,whereasclinicalneu-
ropathy is observed in a much smaller fraction of patients. The
relationship of reduced conduction velocity to hyperalgesia or
impairednerveregenerationisunknown.Concerningthelatter,
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is blocked with tetrodotoxin. Because the nexus between bio-
chemical and electrophysiology disturbances and symptomatic
disturbances are unclear, our studies have focused mainly on
functional end points.
IGF-I and IGF-II Treatments Prevent the Progression
of Hyperalgesia
Supersensitivity to stimuli, or hyperalgesia, is a difﬁcult
management problem in diabetic patients. Hyperalgesia is ob-
servedindiabeticanimals.Mechanicalcompressionelicitspaw
withdrawal when rats feel uncomfortable, and the threshold
force for withdrawal is gradually reduced with the onset of
hyperalgesia in STZ-diabetic rats. Osmotic minipumps were
implanted under the skin that released either vehicle or solvent
in diabetic rats. Infusion of either IGF-I or IGF-II arrested the
progression of hyperalgesia (Zhuang et al., 1996). Hyperalge-
sia also develops in the ZDF (fa/fa) obese and spontaneously
diabetic rat. IGF administration can reverse the hyperalgesia in
this model of type II diabetes (Zhuang et al., 1997).
IGF-I and IGF-II Treatments Prevent or Reverse Impaired
Nerve Regeneration
There is daily wear-and-tear on the nervous system, and a
needtoregeneratenerveterminals.Nerveregenerationisshown
to be impaired in diabetes (Longo et al., 1986; Ekstrom and
Tomlinson, 1989), and this may directly contribute to the loss
of synapses and the dying back of axons.
Because it is known that IGFs normally regulate nerve re-
generation (Kanje et al., 1989; Near et al., 1992; Glazner et al.,
1993), and that IGF gene expression is reduced in diabetic
nerves (Wuarin et al., 1995), the IGF theory (Ishii, 1995) pre-
dicts that replacement IGF therapy should prevent impaired
nerve regeneration in diabetes. Localized infusion of IGF-I
alongside a crush-injured nerve was shown to prevent the im-
pairmentofsciaticnerveregenerationinSTZ-diabeticrats(Ishii
and Lupien, 1995). Additional studies now reveal that systemic
infusion of IGF-I or IGF-II can prevent or reverse impaired
nerveregeneration(IshiiandLupien,1995;Zhuangetal.,1996;
1997). Single daily subcutaneous injections are effective as
well. These studies show that systemically administered IGFs
can act on nerve cells, and the blood-nerve barrier is not an im-
pediment. Systemically administered IGFs can reach ganglion
cells via fenestrated capillaries, have access to nerve terminals,
and can probably reach axons at nodes of Ranvier as well.
IGF-I Treatment Reverses Neuraxonal Dystrophy
Daily subcutaneous injections of IGF-I can reverse ultra-
structuraldamagetothesympatheticnervoussystem.Thistreat-
mentreversesby86%theneuroaxonaldystrophyinthesuperior
mesentericganglionandilealmesentericnervesinratsdiabetic
for 6 months (Schmidt et al., 1999). Neuroaxonal dystrophy is
the hallmark of diabetic autonomic neuropathy, characterized
by swollen preterminal axons and synapses, and shown in tis-
suesobtainedatautopsyfromdiabetichumansubjects(Schmidt
et al., 1993).
IGF-I Treatment Prevents Impaired Wound Healing
Wounds heal poorly in diabetic patients, often progressing
to gangrene and limb amputations. The poor healing is closely
associated with development of neuropathy in diabetes. This
is not unexpected, because nerve injuries in themselves can
produce tissue atrophy, and the health of limbs is dependent
on an adequate nerve supply. IGF-I mRNA levels are reduced
in the gut mucosa, and gastric lesions heal poorly in diabetic
rats (Korolkiewicz et al., 2000). These investigators showed
that subcutaneous administration of IGF-I normalizes wound
healing in diabetic rats.
IGF-I Administered Systemically Crosses the Blood-CNS
Barrier and Prevents Impaired Learning/Memory
It is generally regarded that large molecules the size of IGFs
(molecular weight 7.5 kDa) do not cross the blood-CNS bar-
rier. It would appear, therefore, that to treat the CNS with IGFs,
an access hole would need to be drilled through the skull, a
procedure associated with signiﬁcant risk of surgical mishap
or infection. However, recent studies show that IGFs can cross
the blood-CNS barrier. In a pioneering study, 8 minutes after
injection of 125I-IGF-I or 125I-IGF-II into the carotid artery,
radioactivity was detected in brain parenchyma by autoradio-
graphy of brain slices (Reinhardt and Bondy, 1994). However,
thehalf-lifeoffreeIGFis5to10minutes,andin8minutes,ap-
proximately half of the radioactive IGF would be metabolized.
Because only a small percentage of the radioactivity enters the
brain, it was unclear whether the radioactivity detected in brain
parenchyma represented radioactive free iodine, iodinated IGF
fragments, or intact IGF. This issue was resolved by withdraw-
ing cerebrospinal ﬂuid (CSF) after injecting 125I-IGF-I into the
carotid artery. The radioactivity in the CSF was subjected to
sodium dodecyl sulfate (SDS) gel electrophoresis, and some of
the radioactivity was observed to migrate together with authen-
tic IGF, showing that intact IGF molecules did cross the blood-
CNSbarrier(Armstrongetal.,2000).Furtherstudyshowedthat
the uptake of IGF into CSF was saturable, indicating that there
was an IGF transport molecule at the blood-CNS barrier, and
that the uptake process did not require IGF binding to IGFBP
nor to the type I IGF receptor (Armstrong et al., 2000; Pulford
andIshii,2001).Calculationsshowedthatthecirculatinglevels
of endogenous IGF could contribute substantially to the IGF in
CSF, indicating that there is communication between IGF in
blood and brain.IGF REPLACEMENT THERAPY 263
Lesions are present in the central nervous system of diabetic
patients. For example, the brain ventricles are enlarged, show-
ing brain shrinkage (Dejgaard et al., 1991; Araki et al., 1994).
LearningandmemoryareimpairedintypeI(Ryanetal.,1993)
and elderly type II (Perlmuter et al., 1984; Tun et al., 1990) di-
abetic patients. The incidence of dementia is nearly doubled in
diabetes, even in patients without cerebrovascular disease (Ott
etal.,1999).Likehumans,STZ-diabeticratshavereducedbrain
weight(Lupienetal.,2002),mostlikelyasaconsequenceofre-
duced size of the brain transcript pool (Wuarin et al., 1996) and
impairedlearning/memory(Biesselsetal.,1996).IGFscansup-
port hippocampal neurons (Cheng and Mattson, 1992), and the
hippocampus plays a role in several forms of learning/memory.
IGF is essential for learning/memory, because infusion of an
anti-IGF antibody into the lateral ventricles of the brain can
block the acquisition of learning/memory (Lupien et al., 2002).
IGF gene expression is reduced in the brain and spinal cord
in diabetes as discussed above. As in the case of the PNS,
these neurobiological observations, based on the IGF theory
(Ishii, 1995), led to the prediction that IGF replacement would
prevent cognitive disturbances in diabetes. In fact it is found
that IGF-I administered by subcutaneous infusion can cross the
blood-CNS barrier and prevent impaired learning/memory in
diabetic rats (Lupien et al., 2002). IGF treatment may prevent
learning/memory disturbances and progression to dementia in
diabetic patients.
IGF Replacement Therapy Prevents
Neuropathy During Ongoing Hyperglycemia
Many patients are unable to institute or maintain tight glu-
cose control, and many even with excellent glucose control
develop neuropathy. A treatment to prevent diabetic neuropa-
thy that is effective independently of glycemic state would
be welcome. Systemic as well as local infusion of IGF-I or
IGF-II prevents or reverses hyperalgesia (Zhuang et al., 1996,
1997), impaired nerve regeneration (Ishii and Lupien, 1995;
Zhuang et al., 1996), impaired wound healing (Korolkiewicz
et al., 2000), and disturbances in learning/memory (Lupien
et al., 2002) independently of ongoing hyperglycemia and hy-
poinsulinemia in type I diabetic rats. In the latter study, rats
had ongoing hyperglycemia for 11.5 weeks. A sensitive index
of metabolic disturbance is weight loss, and the IGF treatment
did not prevent weight loss in these investigations. The doses
of IGF in these studies were small physiological replacement
doses (5 to 20 µg/rat/day). Because IGF-I administration can
reduceamyloid-beta,whichisimplicatedinthepathogenesisof
Alzheimer’s disease (Carro et al., 2002), this form of treatment
may prevent memory disturbances in Alzheimer’s disease as
well.
In studies reversing neuraxonal dystrophy, a higher dose of
IGF-I was injected, subcutaneously, such that glucose levels
were transiently signiﬁcantly reduced for 1 to 2 hours from
427 mg/dL to 418 mg/dL (Schmidt et al., 1999). A control
group was treated with a low dose of insulin to replicate the
transient IGF effect on glucose, and insulin, unlike IGF, did
not reverse neuraxonal dystrophy. Consequently, neuraxonal
dystrophy most likely is speciﬁcally reversed by IGF rather
than the transient partial reduction in hyperglycemia.
IGF treatment reversed hyperalgesia in the ZDF (fa/fa)
model of type II diabetes independently of hyperglycemia, hy-
perinsulinemia, and weight gain (Zhuang et al., 1997). There-
fore, IGF treatment can prevent neuropathy in type I or type II
diabetes irrespective of hyperglycemia or direction of weight
change. Taken together, the data show that diabetic neurolog-
ical disorders as well as nephropathy can be treated indepen-
dently of hyperglycemia. It is clear that extensive biochemical
pathways involved in the etiology of neuropathy and nephropa-
thy are not blocked by the consequences of hyperglycemia,
and manipulation of growth factor levels can prevent diabetic
complications.
PHARMACOKINETICS OF IGFs
The pharmacokinetics of IGFs in man has been reviewed
(Ishii and Pu, 1999). The half-life of IGF-I is 8 to 20 hours
due to the formation of complexes with IGFBPs. The daily
productionisabout40to50µgperkgperday,andthevolumeof
distributionisabout0.18L/kg.Clinicallyefﬁcaciouslevelscan
bemaintainedforatleast16hoursbythesubcutaneousrouteof
administration.ThepharmacokineticsofIGF-IIappearssimilar
from studies in a few patients, but additional study is needed in
larger numbers of subjects. These pharmacokinetic parameters
indicatethatclinicaltrialsmaybeconductedusingasingledaily
subcutaneous injection of IGFs. Formulation to enhance the
stability and extend the duration of IGFs would not be needed.
The daily production rate indicates that the most appropri-
ate IGF dose would be in the range of 15 to 40 µg/kg/day. This
is a replacement dose, and replacement doses are effective in
diabetic rats. There are many successful examples of replace-
ment therapy. For example, insulin is replacement therapy for
diabetes in type I diabetic patients, glucocorticoids (cortisol,
prednisone,dexamethasone)arereplacementtherapyforAddi-
son’s disease, and mineralocorticoids are replacement therapy
for adrenal insufﬁciency.
Many diabetic patients are trained in self-administration of
insulin, and could easily adapt to IGF. There is a 50% failure
ratewithin5yearsofinitiatinguseoforalhypoglycemicagents
intypeIIdiabetes,andmanyofthesepatientsconverttoinsulin
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self-inject insulin, and daily IGF subcutaneous administration
would require a minimum of patient education.
SAFETY OF IGF ADMINISTRATION
HumansnormallyhavehighlevelsofIGF-IandIGF-IIinthe
circulation.Becausethegoalofreplacementtherapyistoreturn
the depleted levels of IGF in diabetic patients back to normal,
sideeffectsarenotanticipated.Thesafetyandpharmacologyof
IGFs have been reviewed (Ishii and Pu, 1999). A good deal has
been learned about the safety of IGF products. No signiﬁcant
side effects were encountered in diabetic patients treated for
24weekswith20and40µg/kg/dayIGF-I(Acerinietal.,1997).
Both retinopathy and nephropathy were monitored, and IGF-I
did not cause progression. IGF-I is approved for the treatment
of Laron dwarfs in Japan. These patients have growth hormone
deﬁciency and an extreme form of insulin resistance; high IGF
doses are administered.
Vascular endothelial growth factor (VEGF) is believed to
contribute to diabetic proliferative retinopathy, but conclusive
evidence of IGF-1 involvement in diabetic retinopathy is lack-
ing. In a careful study, Simo et al. (2002) measured IGF-I
as well as VEGF levels in the vitreous ﬂuid from diabetic
patients with retinopathy and corrected for increased leaki-
ness of retinal blood vessels. After correcting for serum pro-
teins, it was found that VEGF levels are signiﬁcantly higher,
whereas free active IGF-I levels are lower in the vitreous of
patients with proliferative diabetic retinopathy versus nondi-
abetic subjects. Moreover, IGF-I mRNA levels are lower in
diabetic versus nondiabetic retinas in humans (Gerhardinger
et al., 2001) and rats (Lowe et al., 1995). Consequently, free
IGF-I levels are not correlated with VEGF levels or prolifera-
tive retinopathy. These data are consistent with the observation
that an increased incidence of retinopathy is not observed in
acromegaly patients with or without diabetes (Ballintine et al,
1981; Sonken et al., 1993; Cogessal and Root, 1940). Growth
hormone increases IGF-I and GH is increased in acromegaly.
In a 2-year prospective study in type II diabetic patients, the
level of IGF-I was progressively reduced during insulin treat-
ment,whereasretinopathyprogressivelyworsened;norelation-
ship was established between level of IGF-I and progression of
retinopathy (Henricsson et al., 1999). In a 6-year study, Wang
et al. (1995) came to the same conclusion. Intraocular IGF-I
levels are mainly derived from the circulation because IGF-I
as well as serum albumin together leak into the eye in ad-
vanced disease (Spranger et al., 2000). Early treatment with
an IGF-I analog can prevent early predegenerative changes in
diabetic retina (Kummer et al., 2003). A somatostatin analog,
ocreotide, was reported to prevent the progression of prolifer-
ative diabetic retinopathy (Grant et al., 2000). Gehrs (2001),
however, pointed out the problems in the experimental design,
includingthatthebaselineretinopathyscoresofthecontroland
treated groups were not compared, the treated group had lower
HbA1C levels, and treated patients may have managed them-
selves better because there was an open label design. Hence,
these results were not interpretable. Further studies would be
useful.
Unnaturally high, or supraphysiological, doses of IGF-I can
cause side effects (reviewed in Ishii and Pu, 1999). High doses
of IGF-I (60 to 220 µg/kg/day, subcutaneous) intended to pre-
vent hyperglycemia in type II diabetic patients may cause side
effects, including hypoglycemia, arthalgia, myalgia, edema,
bilateral jaw tenderness, tachycardia, papilledema, orthostatic
hypotension, nausea, facial pallor or ﬂushing, hand tremors,
headaches, dyspnea, and hand erythema. These untoward ef-
fectswereallreversiblefollowingwithdrawalofIGFtreatment.
IGF-I doses below 50 µg/kg/day are well tolerated.
IGF-II is not, but IGF-I is, associated with prostate cancer
(Chan et al., 1998). IGF-I is also associated with breast cancer.
IGF-I levels may be elevated because tumors produce IGF-I.
Similarly,insulinisamitogenandisproducedbysometumors.
The safety issues for IGFs and insulin have many similarities.
For example, normal humans have approximately 150 ng/mL
IGF-I and 400 ng/mL IGF-II in their circulation, but normal
humans do not have an abnormal risk of cancer. Generally can-
cer risk increases with aging when IGF-I levels are reduced
(Tan and Baxter, 1986). In diabetic neuropathy, patients have
50%reducedlevelsofIGF-I,andreplacementtherapyintended
to normalize IGF levels is not expected to increase cancer risk.
ReturningIGFlevelstonormalindiabeticpatientsseemslikely
to be associated with normal, not excessive, risk. Interestingly,
diabetic patients have been treated for decades with insulin,
and the high doses of insulin at the subcutaneous injection site
would cross-occupy type I IGF receptors, but this is not known
to increase cancer risk.
Growth hormone is used clinically and can elevate IGF-I
levels. Cohen et al. (2000) have reviewed the risks and con-
cluded that causality has not been established between cancer
riskandIGF-Ilevels,andthatgrowthhormone–treatedpatients
inwhichIGF-Ilevelsarebroughtuptonormallevelsshouldnot
have cancer risk increased above the normal population. Circu-
lating IGF-I appears to have less effect on tissue growth than
IGF-I produced within tissues. This is clear because inactiva-
tionoftheIGF-Igeneexclusivelyinliver,whichresultsin70%
reduction of circulating IGF-I, has no effect on body weight
or length in mice (Yakar et al., 1999). This result suggests that
the administration of IGF to increase circulating levels is much
less likely to cause cancer risk than experimental procedures in
which the IGF gene is overexpressed in tissues of transgenic
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Nevertheless, there is the important issue of whether IGF
may cause progression of existing tumors. Colon adenocarci-
nomas developed more rapidly when transplanted to mice with
higher IGF-I levels (Wu et al., 2002). As in other forms of
hormonereplacementtherapy,itwouldseemprudentthatIGF-I
be contraindicated in existing tumors.
CONCLUSIONS
A decline in IGF activity is proposed to contribute to
the pathogenesis of diabetic neurological complications (Ishii,
1995). This theory provides a rational basis both for the design
of testable hypotheses and therapeutic treatment. The theory
predicts with a high success rate that IGF treatment, intended
to replace the IGF levels diminished in diabetes, can prevent or
reverse diabetic neurological disturbances, particularly those
neural functions normally governed by IGFs. The observation
that IGF replacement therapy can prevent or reverse neuro-
logical disturbances in both the central and peripheral nervous
systems in diabetes is a powerful indication that these neuro-
logical disturbances share a common etiology, namely loss of
IGFactivity.Heretofore,theliteratureoncentralandperipheral
neurological diabetic disturbances have been separate, and the
new data may help merge these ﬁelds of investigation.
The theory further predicts and ﬁnds that IGF may pre-
vent neurological disturbances independently of ongoing hy-
perglycemia. Clinical trial shows that the progression of renal
disease likewise can be prevented in diabetic patients by treat-
ments that do not target glycemic control. These data together
show that a large number of complex biochemical pathways in-
volving pathogenetic processes in peripheral nerve, brain, and
kidneysarenotblockedbytheconsequencesofhyperglycemia.
Disturbances to these pathways can be prevented and/or re-
versed by increasing or inhibiting growth factor responses in-
dependently of ongoing hyperglycemia. This realization may
help fuel the development of new therapeutic approaches to
treat diabetic complications.
The pharmacokinetic and safety proﬁles of IGFs are satis-
factory for consideration of clinical trials for IGF treatment of
diabetic neuropathy. A major challenge is to ﬁnd support for
clinical trials. For example, there is no mechanism by which
the National Institutes of Neurological Disorders and Stroke
or National Institute of Diabetes, Digestive and Kidney Dis-
orders can fund the acquisition of clinical grade IGFs for tri-
als. The cost of drug acquisition can exceed the other costs
of a clinical trial. A change in Institute policy is needed to
permit basic research developed under National Institutes of
Health(NIH)-fundedresearchtoberapidlymovedintotheclin-
ics. The National Cancer Institute provides a model by which
manufacturing might be accomplished. It supports a center that
synthesizespromisingsmalldrugcandidatesundermanufactur-
ingguidelinessetbytheFoodandDrugAdministration(FDA).
A similar center is needed for the synthesis of promising thera-
peutic proteins. The successful human genome project is likely
touncovermanyadditionalpromisingtherapeuticproteins,and
the efﬁcient testing of new therapies will be greatly aided by
the availability of an NIH-supported center for the production
of clinical grade therapeutic proteins.
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